Crisis Of Low Supply, High Demand Means Big Opportunity
Right now helium is one of world's best investments. It's Earth's most nonrenewable resource and it's fast running out. That's a crisis because helium is a critical in medical diagnostics, military weapons, and semiconductors, which are the chips that run all the 21st century's gadgets, appliances, and vehicles.
Get a free report that shows you how its supply
Vineet R. Jindal, insider at Reneo Pharmaceuticals
Vineet R. Jindal Insider Alerts

Get notified the next time Vineet R. Jindal buys or sells Reneo Pharmaceuticals stock. Enter your email address below to get our daily insider buying and selling report.

Vineet R. Jindal Insider Information

Vineet R. Jindal founded Stockr, Inc. and Bay Street Advisors, Inc. Presently, he holds the position of Chief Financial Officer for Reneo Pharmaceuticals, Inc.

Mr. Jindal previously held the position of Chief Executive Officer & Director at Stockr, Inc., Vice President-Corporate Communications & Strategy at Reata Pharmaceuticals, Inc., Chief Business Officer at Caliber Corporate Advisers LLC, President, Chief Executive Officer & Director at Viper Gold Ltd., President, Chief Executive Officer & Director at QuikFlo Health, Inc., Principal at Boston Millennia Partners, Analyst at Wedbush Securities, Inc. and Principal at ThinkEquity Partners.

Vineet R. Jindal received a graduate degree from Cornell University and an undergraduate degree and a graduate degree from the University of California, Berkeley.

What is Vineet R. Jindal's net worth?

The estimated net worth of Vineet R. Jindal is at least $35,050.00 as of August 25th, 2021. Mr. Jindal owns 5,000 shares of Reneo Pharmaceuticals stock worth more than $35,050 as of November 30th. This net worth estimate does not reflect any other investments that Mr. Jindal may own. Learn More.

How old is Vineet R. Jindal?

Mr. Jindal is currently 44 years old. There are 5 older executives and no younger executives at Reneo Pharmaceuticals. Learn More.

How do I contact Vineet R. Jindal?

The corporate mailing address for Mr. Jindal and other Reneo Pharmaceuticals executives is , , . Reneo Pharmaceuticals can also be reached via phone at 858-283-0280 and via email at [email protected]

Has Vineet R. Jindal been buying or selling shares of Reneo Pharmaceuticals?

Vineet R. Jindal has not been actively trading shares of Reneo Pharmaceuticals during the last quarter. Most recently, on Wednesday, August 25th, Vineet R. Jindal bought 5,000 shares of Reneo Pharmaceuticals stock. The stock was acquired at an average cost of $7.44 per share, with a total value of $37,200.00. Following the completion of the transaction, the chief financial officer now directly owns 5,000 shares of the company's stock, valued at $37,200.

Who are Reneo Pharmaceuticals' active insiders?

Reneo Pharmaceuticals' insider roster includes Michael Cruse (VP), Gregory Flesher (CEO), Vineet Jindal (CFO), and Bali Muralidhar (Director).

Are insiders buying or selling shares of Reneo Pharmaceuticals?

In the last twelve months, Reneo Pharmaceuticals insiders bought shares 12 times. They purchased a total of 1,281,891 shares worth more than $17,881,825.77. The most recent insider tranaction occured on August, 25th when CFO Vineet R Jindal bought 5,000 shares worth more than $37,200.00.

Information on this page was last updated on 8/25/2021.

Vineet R. Jindal Insider Trading History at Reneo Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/25/2021Buy5,000$7.44$37,200.005,000View SEC Filing Icon  
See Full Table

Vineet R. Jindal Buying and Selling Activity at Reneo Pharmaceuticals

This chart shows Vineet R Jindal's buying and selling at Reneo Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Reneo Pharmaceuticals Company Overview

Reneo Pharmaceuticals logo
Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. The company was incorporated in 2014 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $7.01
Low: $6.93
High: $7.28

50 Day Range

MA: $7.40
Low: $6.31
High: $8.85

2 Week Range

Now: $7.01
Low: $6.10
High: $17.18


15,162 shs

Average Volume

67,995 shs

Market Capitalization

$171.21 million

P/E Ratio


Dividend Yield



Investor Alert: Argentina Loaded With "White Gold" Opportunity
Experts expect the global lithium market to grow by 500% due to the explosion of electric vehicles and green energy. And one small-cap company just snagged a large lithium deposit in a renowned South American location.
Read about this once-in-a-lifetime opportunity